|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
|
BE1009856A5
(fr)
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
|
CA2230748C
(en)
*
|
1997-03-14 |
2010-08-03 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
|
DK1064942T3
(da)
*
|
1998-03-26 |
2004-11-01 |
Fujisawa Pharmaceutical Co |
Sustained release-fremstilling af et makrolid
|
|
JP3718341B2
(ja)
|
1998-05-12 |
2005-11-24 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロースとその製造方法
|
|
US6350786B1
(en)
*
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
|
AU2003200370B2
(en)
*
|
1998-12-07 |
2005-10-27 |
Novartis Ag |
Stabilization of macrolides
|
|
GB9826882D0
(en)
|
1998-12-07 |
1999-01-27 |
Novartis Ag |
Organic compounds
|
|
JP2002544167A
(ja)
|
1999-05-10 |
2002-12-24 |
ノバルティス アクチエンゲゼルシャフト |
有機化合物
|
|
EP1054019A1
(en)
*
|
1999-05-18 |
2000-11-22 |
Shin-Etsu Chemical Co., Ltd. |
Low-substituted hydroxypropyl cellulose
|
|
CA2381425A1
(en)
|
1999-08-24 |
2001-03-01 |
Cellgate, Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
|
US20070032853A1
(en)
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
|
US6680069B1
(en)
|
1999-11-09 |
2004-01-20 |
Shin-Etsu Chemical Co., Ltd. |
Low-substituted hydroxypropyl cellulose and process for manufacturing the same
|
|
CA2359945C
(en)
|
1999-11-12 |
2011-04-26 |
Abbott Laboratories |
Inhibitors of crystallization in a solid dispersion
|
|
US7364752B1
(en)
|
1999-11-12 |
2008-04-29 |
Abbott Laboratories |
Solid dispersion pharamaceutical formulations
|
|
RU2264405C2
(ru)
*
|
1999-12-06 |
2005-11-20 |
Новартис Аг |
40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
|
|
JP3552160B2
(ja)
|
2000-01-14 |
2004-08-11 |
信越化学工業株式会社 |
低置換度ヒドロキシプロピルセルロース粒子の形成方法
|
|
IL134701A0
(en)
*
|
2000-02-23 |
2001-04-30 |
J P M E D Ltd |
Homogeneous solid matrix containing vegetable proteins
|
|
DE10026698A1
(de)
*
|
2000-05-30 |
2001-12-06 |
Basf Ag |
Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
|
|
US20040018228A1
(en)
*
|
2000-11-06 |
2004-01-29 |
Afmedica, Inc. |
Compositions and methods for reducing scar tissue formation
|
|
JP2005512946A
(ja)
*
|
2001-05-09 |
2005-05-12 |
ノバルティス アクチエンゲゼルシャフト |
選択的免疫調節法
|
|
US20040137066A1
(en)
*
|
2001-11-26 |
2004-07-15 |
Swaminathan Jayaraman |
Rationally designed therapeutic intravascular implant coating
|
|
US6641611B2
(en)
|
2001-11-26 |
2003-11-04 |
Swaminathan Jayaraman |
Therapeutic coating for an intravascular implant
|
|
GB0123400D0
(en)
*
|
2001-09-28 |
2001-11-21 |
Novartis Ag |
Organic compounds
|
|
AU2006218279B2
(en)
*
|
2001-09-28 |
2009-12-10 |
Novartis Ag |
Pharmaceutical compositions comprising colloidal silicon dioxide
|
|
US6939376B2
(en)
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
US7682387B2
(en)
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
|
ATE395044T1
(de)
|
2002-02-01 |
2008-05-15 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
|
|
MXPA04007428A
(es)
*
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido.
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
JP3956114B2
(ja)
*
|
2002-06-28 |
2007-08-08 |
インターナショナル・ビジネス・マシーンズ・コーポレーション |
表示制御方法、これを用いたプログラム、情報処理装置及び光学式文字読み取り装置
|
|
PL376169A1
(en)
*
|
2002-11-15 |
2005-12-27 |
Novartis Ag |
Drug delivery system
|
|
AR043504A1
(es)
*
|
2003-03-17 |
2005-08-03 |
Novartis Ag |
Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
|
|
US7160867B2
(en)
*
|
2003-05-16 |
2007-01-09 |
Isotechnika, Inc. |
Rapamycin carbohydrate derivatives
|
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
|
CN1819817A
(zh)
*
|
2003-07-09 |
2006-08-16 |
株式会社钟根堂 |
一种泰克利玛的固体分散体
|
|
JP2007501218A
(ja)
*
|
2003-08-04 |
2007-01-25 |
ファイザー・プロダクツ・インク |
非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
|
|
US8025899B2
(en)
|
2003-08-28 |
2011-09-27 |
Abbott Laboratories |
Solid pharmaceutical dosage form
|
|
US8377952B2
(en)
*
|
2003-08-28 |
2013-02-19 |
Abbott Laboratories |
Solid pharmaceutical dosage formulation
|
|
RU2345999C2
(ru)
*
|
2003-09-03 |
2009-02-10 |
Уайт |
Аморфный 42-эфир рапамицина и 3-гидрокси-2(гидроксиметил)-2-метилпропионовой кислоты и содержащие его фармацевтические композиции
|
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
|
US7780973B2
(en)
*
|
2003-12-15 |
2010-08-24 |
Ethicon Endo-Surgery, Inc. |
Method and device for minimally invasive implantation of biomaterial
|
|
US20050142161A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Freeman Lynetta J. |
Collagen matrix for soft tissue augmentation
|
|
JP2007517879A
(ja)
*
|
2004-01-08 |
2007-07-05 |
ワイス |
Ｃｃｉ−７７９経口投与用の直接圧縮可能な医薬組成物
|
|
US7655442B2
(en)
|
2004-01-29 |
2010-02-02 |
Eisai R&D Management Co., Ltd. |
Method for stabilizing macrolide compounds
|
|
PL2708225T3
(pl)
|
2004-04-23 |
2019-07-31 |
Cydex Pharmaceuticals, Inc. |
Formulacja DPI zawierająca eter sulfoalkilowy cyklodekstryny
|
|
ATE483716T1
(de)
|
2004-08-27 |
2010-10-15 |
Cordis Corp |
Lösungsmittelfreies amorphes rapamycin
|
|
US20060094744A1
(en)
*
|
2004-09-29 |
2006-05-04 |
Maryanoff Cynthia A |
Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
|
|
US20060088591A1
(en)
*
|
2004-10-22 |
2006-04-27 |
Jinghua Yuan |
Tablets from a poorly compressible substance
|
|
KR100678824B1
(ko)
*
|
2005-02-04 |
2007-02-05 |
한미약품 주식회사 |
용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
JP4974903B2
(ja)
|
2005-02-09 |
2012-07-11 |
参天製薬株式会社 |
疾患または状態を処置するための液体処方物
|
|
AU2006222409A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Lifecycle Pharma A/S |
Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
|
|
EP2327429B1
(en)
*
|
2005-03-23 |
2014-09-17 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
|
US20060240108A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Bernard Bobby L |
Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
|
|
DE102005026755A1
(de)
*
|
2005-06-09 |
2006-12-14 |
Basf Ag |
Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
|
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
CA2629714A1
(en)
|
2005-11-14 |
2007-05-24 |
Ariad Gene Therapeutics, Inc. |
Administration of an mtor inhibitor to treat patients with cancer
|
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
|
WO2007092620A2
(en)
|
2006-02-09 |
2007-08-16 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
|
PL2001466T3
(pl)
|
2006-03-23 |
2016-06-30 |
Santen Pharmaceutical Co Ltd |
Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
|
|
US7883855B2
(en)
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
|
EP1938800A1
(en)
|
2006-12-06 |
2008-07-02 |
Ranbaxy Laboratories Limited |
Sirolimus nanodispersion
|
|
CA2673296C
(en)
|
2006-12-29 |
2012-10-16 |
Abbott Laboratories |
Improved assay for immunosuppressant drugs
|
|
US7914999B2
(en)
|
2006-12-29 |
2011-03-29 |
Abbott Laboratories |
Non-denaturing lysis reagent
|
|
CA2673314C
(en)
|
2006-12-29 |
2014-03-11 |
Abbott Laboratories |
Non-denaturing lysis reagent for use with capture-in-solution immunoassay
|
|
WO2008082979A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Diagnostic test for the detection of a molecule or drug in whole blood
|
|
EP1952807A1
(en)
*
|
2007-01-24 |
2008-08-06 |
LEK Pharmaceuticals D.D. |
Sirolimus formulation
|
|
MX2010010050A
(es)
|
2008-03-20 |
2011-03-15 |
Virun Inc Star |
Emulsiones que incluyen un derivado de polietilen glicol de tocoferol.
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
EP2365802B1
(en)
|
2008-11-11 |
2017-08-02 |
The Board of Regents,The University of Texas System |
Microcapsules of rapamycin and use for treating cancer
|
|
FR2943539B1
(fr)
|
2009-03-31 |
2011-07-22 |
Ethypharm Sa |
Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
|
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
|
TWI532484B
(zh)
*
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
TWI540132B
(zh)
*
|
2009-06-08 |
2016-07-01 |
亞培公司 |
Ｂｃｌ-２族群抑制劑之口服醫藥劑型
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
US20170079962A1
(en)
|
2009-11-11 |
2017-03-23 |
Rapamycin Holdings, Llc |
Oral Rapamycin Preparation and Use for Stomatitus
|
|
SG10201500152UA
(en)
*
|
2009-12-22 |
2015-03-30 |
Abbvie Inc |
Abt-263 capsule
|
|
CN103037708B
(zh)
|
2010-03-23 |
2015-05-20 |
维尔恩公司 |
含有蔗糖脂肪酸酯的纳米乳液
|
|
EP2563391B1
(en)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
|
IT1400977B1
(it)
*
|
2010-07-01 |
2013-07-05 |
Euticals Spa |
Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
|
|
CA3152557A1
(en)
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
PT2643322T
(pt)
|
2010-11-23 |
2017-11-13 |
Abbvie Inc |
Sais e formas cristalinas de um agente indutor de apoptose
|
|
TWI620736B
(zh)
|
2010-11-23 |
2018-04-11 |
艾伯維巴哈馬有限公司 |
使用選擇性ｂｃｌ-２抑制劑之治療方法
|
|
US20120172796A1
(en)
|
2010-12-30 |
2012-07-05 |
Chappa Ralph A |
Composition for intravascular delivery of therapeutic composition
|
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
|
US20120303115A1
(en)
*
|
2011-05-25 |
2012-11-29 |
Dadino Ronald C |
Expandable devices coated with a rapamycin composition
|
|
JP2014516075A
(ja)
|
2011-06-06 |
2014-07-07 |
シェブロン フィリップス ケミカル カンパニー エルピー |
癌治療のためのメタロセン化合物の使用
|
|
KR101151890B1
(ko)
*
|
2011-08-11 |
2012-05-31 |
동아제약주식회사 |
안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
|
|
WO2013022201A1
(en)
*
|
2011-08-11 |
2013-02-14 |
Dong-A Pharm. Co., Ltd. |
Process of preparing a stabilized and solubilized formulation of sirolimus derivatives
|
|
JP6368242B2
(ja)
|
2011-10-06 |
2018-08-01 |
ノバルティス アーゲー |
４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
|
|
EP2594260A1
(en)
*
|
2011-11-18 |
2013-05-22 |
LEK Pharmaceuticals d.d. |
Solid preparations comprising sirolimus with desired bioavailability and method for its preparation
|
|
US8912215B2
(en)
*
|
2011-12-13 |
2014-12-16 |
Everon Biosciences, Inc. |
Rapamycin composition
|
|
KR200477251Y1
(ko)
*
|
2011-12-30 |
2015-05-22 |
엘에스산전 주식회사 |
배선용 차단기의 주 접점 위치 표시 기구
|
|
CN103585122B
(zh)
*
|
2012-08-17 |
2017-12-05 |
山东新时代药业有限公司 |
一种含依维莫司的片剂及其制备方法
|
|
US20150290176A1
(en)
|
2012-10-12 |
2015-10-15 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
|
US9610385B2
(en)
*
|
2013-03-07 |
2017-04-04 |
Abbott Cardiovascular Systems Inc. |
Method of fabricating an implantable medical device comprising a rapamycin derivative
|
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
TW201503912A
(zh)
|
2013-03-19 |
2015-02-01 |
Novartis Ag |
包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
|
|
US10682415B2
(en)
|
2013-07-22 |
2020-06-16 |
Wisconsin Alumni Research Foundation |
Thermogel formulation for combination drug delivery
|
|
US10307370B2
(en)
|
2013-10-08 |
2019-06-04 |
AI Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
CN105899232A
(zh)
|
2013-11-13 |
2016-08-24 |
诺华股份有限公司 |
用于增强免疫应答的mTOR抑制剂
|
|
CN103610646B
(zh)
*
|
2013-12-05 |
2015-07-15 |
江苏奥赛康药业股份有限公司 |
一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
CN104721158B
(zh)
*
|
2013-12-24 |
2018-01-30 |
正大天晴药业集团股份有限公司 |
一种稳定的依维莫司片剂
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
AU2014373683B2
(en)
|
2013-12-31 |
2020-05-07 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
|
US10307371B2
(en)
|
2014-02-11 |
2019-06-04 |
AI Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
KR20160120739A
(ko)
|
2014-02-11 |
2016-10-18 |
램 테라퓨틱스, 인코포레이티드 |
림프관평활근종증의 치료를 위한 라파마이신
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
CA2943609A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
|
DK3125875T3
(da)
|
2014-04-04 |
2023-07-24 |
Ai Therapeutics Inc |
Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
KR20170095807A
(ko)
|
2014-10-07 |
2017-08-23 |
램 테라퓨틱스, 인코포레이티드 |
폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
MA40910A
(fr)
|
2014-11-07 |
2017-09-12 |
Civitas Therapeutics Inc |
Poudres de rapamycine pour administration pulmonaire
|
|
WO2016130645A1
(en)
|
2015-02-10 |
2016-08-18 |
Lam Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
WO2016135740A1
(en)
|
2015-02-23 |
2016-09-01 |
Natco Pharma Limited |
Process for preparing stable oral compositions of everolimus
|
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
HK1245095A1
(zh)
|
2015-05-20 |
2018-08-24 |
Novartis Ag |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
|
ES3063790T3
(en)
|
2015-06-09 |
2026-04-20 |
Lonza Sales Ag |
Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
|
|
US10383860B2
(en)
|
2015-07-28 |
2019-08-20 |
Nippon Kayaku Kabushiki Kaisha |
Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
|
|
JP6793651B2
(ja)
*
|
2015-08-28 |
2020-12-02 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
WO2017038925A1
(ja)
*
|
2015-09-03 |
2017-03-09 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
JP6855470B2
(ja)
|
2016-05-27 |
2021-04-07 |
日本化薬株式会社 |
ラパマイシン又はその誘導体を含有する医薬組成物
|
|
EP3487878A4
(en)
|
2016-07-20 |
2020-03-25 |
University of Utah Research Foundation |
CD229-CAR-T CELLS AND METHOD FOR USE THEREOF
|
|
EP3524232A1
(en)
*
|
2016-10-04 |
2019-08-14 |
Nippon Kayaku Kabushiki Kaisha |
Method for producing solid dispersion containing rapamycin derivative
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
CN110114070A
(zh)
|
2016-11-23 |
2019-08-09 |
诺华公司 |
使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
|
|
CN107080738A
(zh)
*
|
2017-04-26 |
2017-08-22 |
四川制药制剂有限公司 |
乙酰螺旋霉素片的制备方法
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3848065B1
(en)
|
2017-05-15 |
2023-07-26 |
C. R. Bard, Inc. |
Medical device with drug-eluting coating and intermediate layer
|
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3880266B1
(en)
|
2018-11-14 |
2025-05-07 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
|
EP3741367A1
(en)
|
2019-05-21 |
2020-11-25 |
Premark Pharma GmbH |
Treatment of ocular disease
|
|
WO2020261619A1
(ja)
*
|
2019-06-26 |
2020-12-30 |
株式会社リコー |
医薬組成物
|
|
AU2020410545A1
(en)
*
|
2019-12-19 |
2022-08-11 |
Triviumvet Dac |
Veterinary formulations comprising rapamycin and methods of using the same for treating animal diseases
|
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
|
WO2024209038A1
(en)
|
2023-04-06 |
2024-10-10 |
Premark Pharma Gmbh |
Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale
|